within Pharmacolibrary.Drugs.ATC.L;

model L01FE01
  extends Pharmacokinetic.Models.PK_2C(
    weight         = 70,
    F              = 1,
    Cl             = 3.666666666666667e-06,
    adminDuration  = 600,
    adminMass      = 400 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.00309,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,            
    Vdp             = 0.0023599999999999997,
    k12             = 0.29,
    k21             = 0.29
    
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>L01FE01</td></tr><td>route:</td><td>intravenous</td></tr><tr><td>n-compartments</td><td>2</td></tr></table><p>Cetuximab is a chimeric monoclonal antibody that targets the epidermal growth factor receptor (EGFR), used in the treatment of certain types of cancer such as metastatic colorectal cancer and squamous cell carcinoma of the head and neck. It is approved and in clinical use.</p><h4>Pharmacokinetics</h4><p>Population pharmacokinetic parameters in adult patients with advanced solid tumors receiving intravenous infusion.</p><h4>References</h4><ol><li><p>Bou-Assaly, W, &amp; Mukherji, S (2010). Cetuximab (erbitux). <i>AJNR. American journal of neuroradiology</i> 31(4) 626–627. DOI:<a href=\"https://doi.org/10.3174/ajnr.A2054\">10.3174/ajnr.A2054</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/20167650/\">https://pubmed.ncbi.nlm.nih.gov/20167650</a></p></li><li><p>Prabhash, K, et al., &amp; Aiwale, A (2024). Efficacy and Safety of Biosimilar Cetuximab Versus Innovator Cetuximab in Indian Patients With Head and Neck Cancer: A Multicenter, Randomized, Double-Blind, Phase III Trial. <i>JCO global oncology</i> 10 e2400059–None. DOI:<a href=\"https://doi.org/10.1200/GO.24.00059\">10.1200/GO.24.00059</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/39541562/\">https://pubmed.ncbi.nlm.nih.gov/39541562</a></p></li><li><p>Kuilamu, E, et al., &amp; Kaminskas, LM (2020). Cetuximab Exhibits Sex Differences in Lymphatic Exposure after Intravenous Administration in Rats in the Absence of Differences in Plasma Exposure. <i>Pharmaceutical research</i> 37(11) 224–None. DOI:<a href=\"https://doi.org/10.1007/s11095-020-02945-2\">10.1007/s11095-020-02945-2</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/33078255/\">https://pubmed.ncbi.nlm.nih.gov/33078255</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end L01FE01;
